Communiqués Magenta Therapeutics

Actions

MGTA

US55910K1088

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 02/07/2024			Varia. 5j.	Varia. 1 janv.
26,27 ^USD	-9,01%		+8,37%	+134,69%

2023	Dianthus Therapeutics, Inc. a finalisé l'acquisition de Magenta Therapeutics, Inc. (NasdaqGM:MGTA) auprès d'un groupe d'actionnaires dans le cadre d'une opération de fusion inversée.	CI
2023	Magenta Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le semestre clos le 30 juin 2023	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Adrenoleukodystrophy Clinical Trials, and Key Companies\|Companies - Bluebird Bio, Minoryx Therapeutics, MedDay Pharmaceuticals, Magenta Therapeutics, Orpheris Inc, SOM Biotech, and many others	11/09/23	AQ
MAGENTA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Magenta Therapeutics, Inc. - MGTA	07/08/23	BU
Shareholder Alert: Ademi LLP investigates whether Magenta Therapeutics, Inc. has obtained a Fair Price in its transaction with Dianthus	04/05/23	PR
MAGENTA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Magenta Therapeutics, Inc. - MGTA	04/05/23	BU
MGTA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Magenta Therapeutics, Inc. Is Fair to Shareholders	03/05/23	BU
MAGENTA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	03/05/23	AQ
Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement	03/05/23	AQ
MAGENTA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement (form 8-K)	06/04/23	AQ
MAGENTA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	31/03/23	AQ
Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan	31/03/23	AQ
MAGENTA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	23/03/23	AQ
MAGENTA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers (form 8-K)	07/02/23	AQ
MAGENTA THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	02/02/23	AQ
Magenta Therapeutics to Explore Strategic Alternatives	02/02/23	AQ
MAGENTA THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	25/01/23	AQ
Magenta Therapeutics Voluntarily Pauses the MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial to Investigate Drug Safety	25/01/23	AQ
MAGENTA THERAPEUTICS, INC. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)	20/12/22	AQ
Magenta Therapeutics Provides Update for MGTA-117 Phase 1/2 Dose Escalation Clinical Trial	20/12/22	AQ
Magenta Therapeutics : Update on MGTA-117 Presentation	13/12/22	PU
MAGENTA THERAPEUTICS, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)	13/12/22	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Magenta Therapeutics

Actions

MGTA

US55910K1088

Communiqués

Filtres